ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company that is developing the SAPPHIRE II eye test designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (A-beta) signature in their eyes, announced today that it has elected its President and CEO, Paul D. Hartung, as Chairman of the Board. The company also announced that it has elected a new director: Christine de los Reyes, PharmD, Vice President, Business Development and Strategic Planning, Alopexx Enterprises LLC.
On Sept. 30, 2014, Cognoptix announced that it closed the first tranche of a Series D round of financing totaling over $15 million. The round was co-led by new investor Alopexx and existing investor Inventages, with participation from original investor, Launchpad Venture Group.
Help employers find you! Check out all the jobs and post your resume.
